Biotech News
Related news
MXCTMaxCyte2026-05-12 20:06 EST
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MXCTMaxCyte2026-08-12 20:05 EST
MaxCyte Reports Second Quarter 2026 Financial Results
PHARPharming Group2026-07-30 05:00 EST
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
SRPTSarepta Therapeutics2026-08-05 20:05 EST
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
TSHATaysha Gene Therapies2026-08-04 20:00 EST
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
CRSPCRISPR Therapeutics2026-08-03 20:15 EST
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
KRYSKrystal Biotech2026-08-03 11:00 EST
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
NTLAIntellia2026-07-30 12:00 EST
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
OCGNOcugen2026-07-28 20:01 EST
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
PHARPharming Group2026-07-16 06:00 EST
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
MaxCyte
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...
Recent company news
MXCTMaxCyte2026-08-19 12:05 EST
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MXCTMaxCyte2026-08-12 20:05 EST
MaxCyte Reports Second Quarter 2026 Financial Results
MXCTMaxCyte2026-07-21 12:05 EST
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
MXCTMaxCyte2026-07-15 20:05 EST
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
MXCTMaxCyte2026-06-23 13:00 EST
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
Stock data
- Close
- 1.38 USD
- Market cap
- 131.76M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States